<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36972009</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-1950</ISSN><JournalIssue CitedMedium="Internet"><Volume>83</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Drugs</Title><ISOAbbreviation>Drugs</ISOAbbreviation></Journal><ArticleTitle>Targeted Small Molecules for Systemic Lupus Erythematosus: Drugs in the Pipeline.</ArticleTitle><Pagination><StartPage>479</StartPage><EndPage>496</EndPage><MedlinePgn>479-496</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40265-023-01856-x</ELocationID><Abstract><AbstractText>Despite the uncertainty of the pathogenesis of systemic lupus erythematosus, novel small molecules targeting specific intracellular mechanisms of immune cells are being developed to reverse the pathophysiological processes. These targeted molecules have the advantages of convenient administration, lower production costs, and the lack of immunogenicity. The Janus kinases, Bruton's tyrosine kinases, and spleen tyrosine kinases are important enzymes for activating downstream signals from various receptors on immune cells that include cytokines, growth factor, hormones, Fc, CD40, and B-cell receptors. Suppression of these kinases impairs cellular activation, differentiation, and survival, leading to diminished cytokine actions and autoantibody secretion. Intracellular protein degradation by immunoproteasomes, levered by the cereblon E3 ubiquitin ligase complex, is an essential process for the regulation of cellular functions and survival. Modulation of the immunoproteasomes and cereblon leads to depletion of long-lived plasma cells, reduced plasmablast differentiation, and production of autoantibodies and interferon-&#x3b1;. The sphingosine 1-phosphate/sphingosine 1-phosphate receptor-1 pathway is responsible for lymphocyte trafficking, regulatory T-cell/Th17 cell homeostasis, and vascular permeability. Sphingosine 1-phosphate receptor-1 modulators limit the trafficking of autoreactive lymphocytes across the blood-brain barrier, increase regulatory T-cell function, and decrease production of autoantibodies and type I interferons. This article summarizes the development of these targeted small molecules in the treatment of systemic lupus erythematosus, and the future prospect for precision medicine.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mok</LastName><ForeName>Chi Chiu</ForeName><Initials>CC</Initials><Identifier Source="ORCID">0000-0003-3696-1228</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Tuen Mun Hospital, Tsing Chung Koon Road, New Territories, Hong Kong SAR, China. ccmok2005@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drugs</MedlineTA><NlmUniqueID>7600076</NlmUniqueID><ISSNLinking>0012-6667</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004364">Pharmaceutical Preparations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000081025">Sphingosine-1-Phosphate Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>42HK56048U</RegistryNumber><NameOfSubstance UI="D014443">Tyrosine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004364" MajorTopicYN="N">Pharmaceutical Preparations</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000081025" MajorTopicYN="N">Sphingosine-1-Phosphate Receptors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="Y">B-Lymphocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014443" MajorTopicYN="N">Tyrosine</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Chi Chiu Mok has received speaker honoraria from GSK and Pfizer during the recent APLAR 2022 meeting.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>27</Day><Hour>11</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36972009</ArticleId><ArticleId IdType="pmc">PMC10042116</ArticleId><ArticleId IdType="doi">10.1007/s40265-023-01856-x</ArticleId><ArticleId IdType="pii">10.1007/s40265-023-01856-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mok CC. The Jakinibs in systemic lupus erythematosus: progress and prospects. Expert Opin Investig Drugs. 2019;28:85&#x2013;92. doi: 10.1080/13543784.2019.1551358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543784.2019.1551358</ArticleId><ArticleId IdType="pubmed">30462559</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365:2110&#x2013;2121. doi: 10.1056/NEJMra1100359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1100359</ArticleId><ArticleId IdType="pubmed">22129255</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahajan A, Herrmann M, Mu&#xf1;oz LE. Clearance deficiency and cell death pathways: a model for the pathogenesis of SLE. Front Immunol. 2016;7:35. doi: 10.3389/fimmu.2016.00035.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2016.00035</ArticleId><ArticleId IdType="pmc">PMC4745266</ArticleId><ArticleId IdType="pubmed">26904025</ArticleId></ArticleIdList></Reference><Reference><Citation>Fresneda Alarcon M, McLaren Z, Wright HL. Neutrophils in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus: Same foe different M.O. Front Immunol. 2021;12:649693. doi: 10.3389/fimmu.2021.649693.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.649693</ArticleId><ArticleId IdType="pmc">PMC7969658</ArticleId><ArticleId IdType="pubmed">33746988</ArticleId></ArticleIdList></Reference><Reference><Citation>Leffler J, Martin M, Gullstrand B, Tyd&#xe9;n H, Lood C, Truedsson L, et al. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J Immunol. 2012;188:3522&#x2013;3531. doi: 10.4049/jimmunol.1102404.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1102404</ArticleId><ArticleId IdType="pubmed">22345666</ArticleId></ArticleIdList></Reference><Reference><Citation>Hakkim A, F&#xfc;rnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA. 2010;107:9813&#x2013;9818. doi: 10.1073/pnas.0909927107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0909927107</ArticleId><ArticleId IdType="pmc">PMC2906830</ArticleId><ArticleId IdType="pubmed">20439745</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakata K, Nakayamada S, Miyazaki Y, Kubo S, Ishii A, Nakano K, et al. Up-regulation of TLR7-mediated IFN-&#x3b1; production by plasmacytoid dendritic cells in patients with systemic lupus erythematosus. Front Immunol. 2018;9:1957. doi: 10.3389/fimmu.2018.01957.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01957</ArticleId><ArticleId IdType="pmc">PMC6121190</ArticleId><ArticleId IdType="pubmed">30210502</ArticleId></ArticleIdList></Reference><Reference><Citation>Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Investig. 2005;115:407&#x2013;417. doi: 10.1172/JCI23025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI23025</ArticleId><ArticleId IdType="pmc">PMC544604</ArticleId><ArticleId IdType="pubmed">15668740</ArticleId></ArticleIdList></Reference><Reference><Citation>Eloranta ML, Alm GV, R&#xf6;nnblom L. Disease mechanisms in rheumatology&#x2013;tools and pathways: plasmacytoid dendritic cells and their role in autoimmune rheumatic diseases. Arthritis Rheumatol. 2013;65:853&#x2013;863. doi: 10.1002/art.37821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.37821</ArticleId><ArticleId IdType="pubmed">23280551</ArticleId></ArticleIdList></Reference><Reference><Citation>Fransen JH, van der Vlag J, Ruben J, Adema GJ, Berden JH, Hilbrands LB. The role of dendritic cells in the pathogenesis of systemic lupus erythematosus. Arthritis Res Ther. 2010;12:207. doi: 10.1186/ar2966.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar2966</ArticleId><ArticleId IdType="pmc">PMC2888204</ArticleId><ArticleId IdType="pubmed">20423534</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheinecker C, Bonelli M, Smolen JS. Pathogenetic aspects of systemic lupus erythematosus with an emphasis on regulatory T cells. J Autoimmun. 2010;35:269&#x2013;275. doi: 10.1016/j.jaut.2010.06.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2010.06.018</ArticleId><ArticleId IdType="pubmed">20638240</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujio K, Okamura T, Sumitomo S, Yamamoto K. Regulatory cell subsets in the control of autoantibody production related to systemic autoimmunity. Ann Rheum Dis. 2013;72(Suppl 2):ii85&#x2013;ii89. doi: 10.1136/annrheumdis-2012-202341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-202341</ArticleId><ArticleId IdType="pubmed">23253929</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolidis SA, Lieberman LA, Kis-Toth K, Crisp&#xed;n JC, Tsokos GC. The dysregulation of cytokine networks in systemic lupus erythematosus. J Interferon Cytokine Res. 2011;31:769&#x2013;779. doi: 10.1089/jir.2011.0029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2011.0029</ArticleId><ArticleId IdType="pmc">PMC3189553</ArticleId><ArticleId IdType="pubmed">21877904</ArticleId></ArticleIdList></Reference><Reference><Citation>Su DL, Lu ZM, Shen MN, Li X, Sun LY. Roles of pro- and anti-inflammatory cytokines in the pathogenesis of SLE. J Biomed Biotechnol. 2012;2012:347141. doi: 10.1155/2012/347141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/347141</ArticleId><ArticleId IdType="pmc">PMC3303597</ArticleId><ArticleId IdType="pubmed">22500087</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob N, Stohl W. Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther. 2011;13:228. doi: 10.1186/ar3349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar3349</ArticleId><ArticleId IdType="pmc">PMC3239336</ArticleId><ArticleId IdType="pubmed">21745419</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheumatol. 2008;58:2453&#x2013;2459. doi: 10.1002/art.23678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23678</ArticleId><ArticleId IdType="pubmed">18668552</ArticleId></ArticleIdList></Reference><Reference><Citation>Mai L, Asaduzzaman A, Noamani B, Fortin PR, Gladman DD, Touma Z, et al. The baseline interferon signature predicts disease severity over the subsequent 5&#xa0;years in systemic lupus erythematosus. Arthritis Res Ther. 2021;23:29. doi: 10.1186/s13075-021-02414-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-021-02414-0</ArticleId><ArticleId IdType="pmc">PMC7811214</ArticleId><ArticleId IdType="pubmed">33451338</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Fu W, Ranger A, Allaire N, Cullen P, Magder LS, et al. Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus. BMC Med Genom. 2019;12:4. doi: 10.1186/s12920-018-0468-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12920-018-0468-1</ArticleId><ArticleId IdType="pmc">PMC6327466</ArticleId><ArticleId IdType="pubmed">30626389</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang S, Yu Q, Ding C. Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases. Expert Opin Investig Drugs. 2022;31:291&#x2013;303. doi: 10.1080/13543784.2022.2040014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543784.2022.2040014</ArticleId><ArticleId IdType="pubmed">35130124</ArticleId></ArticleIdList></Reference><Reference><Citation>Neys SFH, Rip J, Hendriks RW, Corneth OBJ. Bruton&#x2019;s tyrosine kinase inhibition as an emerging therapy in systemic autoimmune disease. Drugs. 2021;81:1605&#x2013;1626. doi: 10.1007/s40265-021-01592-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-021-01592-0</ArticleId><ArticleId IdType="pmc">PMC8491186</ArticleId><ArticleId IdType="pubmed">34609725</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi J, Zhuang R, Kong L, He R, Zhu H, Zhang J. Immunoproteasome-selective inhibitors: an overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases. Eur J Med Chem. 2019;182:111646. doi: 10.1016/j.ejmech.2019.111646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2019.111646</ArticleId><ArticleId IdType="pubmed">31521028</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs O. Targeting cereblon in hematologic malignancies. Blood Rev. 2023;57:100994. doi: 10.1016/j.blre.2022.100994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2022.100994</ArticleId><ArticleId IdType="pubmed">35933246</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai HC, Han MH. Sphingosine-1-phosphate (S1P) and S1P signaling pathway: therapeutic targets in autoimmunity and inflammation. Drugs. 2016;76:1067&#x2013;1079. doi: 10.1007/s40265-016-0603-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-016-0603-2</ArticleId><ArticleId IdType="pubmed">27318702</ArticleId></ArticleIdList></Reference><Reference><Citation>Burg N, Salmon JE, Hla T. Sphingosine 1-phosphate receptor-targeted therapeutics in rheumatic diseases. Nat Rev Rheumatol. 2022;18:335&#x2013;351. doi: 10.1038/s41584-022-00784-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-022-00784-6</ArticleId><ArticleId IdType="pmc">PMC9641499</ArticleId><ArticleId IdType="pubmed">35508810</ArticleId></ArticleIdList></Reference><Reference><Citation>Stark GR, Darnell JE. The JAK-STAT pathway at twenty. Immunity. 2012;36:503&#x2013;514. doi: 10.1016/j.immuni.2012.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2012.03.013</ArticleId><ArticleId IdType="pmc">PMC3909993</ArticleId><ArticleId IdType="pubmed">22520844</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y, Luo Y, O&#x2019;Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18:133&#x2013;145. doi: 10.1038/s41584-021-00726-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-021-00726-8</ArticleId><ArticleId IdType="pmc">PMC8730299</ArticleId><ArticleId IdType="pubmed">34987201</ArticleId></ArticleIdList></Reference><Reference><Citation>Choy EH. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford) 2019;58:953&#x2013;962. doi: 10.1093/rheumatology/key339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/key339</ArticleId><ArticleId IdType="pmc">PMC6532440</ArticleId><ArticleId IdType="pubmed">30508136</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368:161&#x2013;170. doi: 10.1056/NEJMra1202117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1202117</ArticleId><ArticleId IdType="pmc">PMC7604876</ArticleId><ArticleId IdType="pubmed">23301733</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O&#x2019;Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;17:78. doi: 10.1038/nrd.2017.267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2017.267</ArticleId><ArticleId IdType="pmc">PMC6168198</ArticleId><ArticleId IdType="pubmed">29282366</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadina M, Johnson C, Schwartz D, Bonelli M, Hasni S, Kanno Y, et al. Translational and clinical advances in JAK-STAT biology: the present and future of jakinibs. J Leukoc Biol. 2018;104:499&#x2013;514. doi: 10.1002/JLB.5RI0218-084R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JLB.5RI0218-084R</ArticleId><ArticleId IdType="pubmed">29999544</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77:521&#x2013;546. doi: 10.1007/s40265-017-0701-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-017-0701-9</ArticleId><ArticleId IdType="pmc">PMC7102286</ArticleId><ArticleId IdType="pubmed">28255960</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Alexander M, Gadina M, O&#x2019;Shea JJ, Meylan F, Schwartz DM. JAK-STAT signaling in human disease: from genetic syndromes to clinical inhibition. J Allergy Clin Immunol. 2021;148:911&#x2013;925. doi: 10.1016/j.jaci.2021.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2021.08.004</ArticleId><ArticleId IdType="pmc">PMC8514054</ArticleId><ArticleId IdType="pubmed">34625141</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu LD, Stump KL, Wallace NH, Dobrzanski P, Serdikoff C, Gingrich DE, et al. Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2. J Immunol. 2011;187:3840&#x2013;3853. doi: 10.4049/jimmunol.1101228.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1101228</ArticleId><ArticleId IdType="pubmed">21880982</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Yang N, Zhang L, Huang B, Tan H, Liang Y, et al. Jak/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL/lpr mice. Lupus. 2010;19:1171&#x2013;1180. doi: 10.1177/0961203310367660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203310367660</ArticleId><ArticleId IdType="pubmed">20501525</ArticleId></ArticleIdList></Reference><Reference><Citation>Ripoll &#xc8;, de Ramon L, DraibeBordignon J, Merino A, Bola&#xf1;os N, Goma M, et al. JAK3-STAT pathway blocking benefits in experimental lupus nephritis. Arthritis Res Ther. 2016;18:134. doi: 10.1186/s13075-016-1034-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-016-1034-x</ArticleId><ArticleId IdType="pmc">PMC4898357</ArticleId><ArticleId IdType="pubmed">27278657</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K, Hayakawa K, Fujishiro M, Kawasaki M, Hirai T, Tsushima H, et al. JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation. BMC Immunol. 2017;18:41. doi: 10.1186/s12865-017-0225-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12865-017-0225-9</ArticleId><ArticleId IdType="pmc">PMC5568047</ArticleId><ArticleId IdType="pubmed">28830352</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J, Zhang Y, Wang M, Zhang Y, Li P, Cao Y, et al. Therapeutic effects of tofacitinib on pristane-induced murine lupus. Arch Rheumatol. 2022;37:195&#x2013;204. doi: 10.46497/ArchRheumatol.2022.8252.</Citation><ArticleIdList><ArticleId IdType="doi">10.46497/ArchRheumatol.2022.8252</ArticleId><ArticleId IdType="pmc">PMC9377175</ArticleId><ArticleId IdType="pubmed">36017210</ArticleId></ArticleIdList></Reference><Reference><Citation>Furumoto Y, Smith CK, Blanco L, Zhao W, Brooks SR, Thacker SG, et al. Tofacitinib ameliorates murine lupus and its associated vascular dysfunction. Arthritis Rheumatol. 2017;69:148&#x2013;160. doi: 10.1002/art.39818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39818</ArticleId><ArticleId IdType="pmc">PMC5195893</ArticleId><ArticleId IdType="pubmed">27429362</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Q, Chen W, Song H, Long X, Zhang Z, Tang X, et al. Tofacitinib ameliorates lupus through suppression of T cell activation mediated by TGF-beta type I receptor. Front Immunol. 2021;12:675542. doi: 10.3389/fimmu.2021.675542.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.675542</ArticleId><ArticleId IdType="pmc">PMC8358742</ArticleId><ArticleId IdType="pubmed">34394075</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Park Y, Jang SG, Hong SM, Song YS, Kim MJ, et al. Baricitinib attenuates autoimmune phenotype and podocyte injury in a murine model of systemic lupus erythematosus. Front Immunol. 2021;12:704526. doi: 10.3389/fimmu.2021.704526.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.704526</ArticleId><ArticleId IdType="pmc">PMC8419414</ArticleId><ArticleId IdType="pubmed">34497607</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawasaki M, Fujishiro M, Yamaguchi A, Nozawa K, Kaneko H, Takasaki Y, et al. Possible role of the JAK/STAT pathways in the regulation of T cell-interferon related genes in systemic lupus erythematosus. Lupus. 2011;20:1231&#x2013;1239. doi: 10.1177/0961203311409963.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203311409963</ArticleId><ArticleId IdType="pubmed">21980035</ArticleId></ArticleIdList></Reference><Reference><Citation>Goropev&#x161;ek A, Gorenjak M, Gradi&#x161;nik S, Dai K, Holc I, Hojs R, et al. Increased levels of STAT1 protein in blood CD4 T cells from systemic lupus erythematosus patients are associated with perturbed homeostasis of activated CD45RA-FOXP3hi regulatory subset and follow-up disease severity. J Interferon Cytokine Res. 2017;37:254&#x2013;268. doi: 10.1089/jir.2016.0040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2016.0040</ArticleId><ArticleId IdType="pubmed">28256939</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagberg N, Joelsson M, Leonard D, Reid S, Eloranta ML, Mo J, et al. The STAT4 SLE risk allele rs7574865[T] is associated with increased IL-12-induced IFN-&#x3b3; production in T cells from patients with SLE. Ann Rheum Dis. 2018;77:1070&#x2013;1077. doi: 10.1136/annrheumdis-2017-212794.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-212794</ArticleId><ArticleId IdType="pmc">PMC6029643</ArticleId><ArticleId IdType="pubmed">29475858</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Varga MR, Rodr&#xed;guez-Bayona B, A&#xf1;ez GA, Medina Varo F, P&#xe9;rez Venegas JJ, Brieva JA, et al. Clinical relevance of circulating anti-ENA and anti-dsDNA secreting cells from SLE patients and their dependence on STAT-3 activation. Eur J Immunol. 2017;47:1211&#x2013;1219. doi: 10.1002/eji.201646872.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201646872</ArticleId><ArticleId IdType="pubmed">28463395</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JM, Xu WD, Huang AF. Association of STAT4 Gene Rs7574865, Rs10168266 polymorphisms and systemic lupus erythematosus susceptibility: a meta-analysis. Immunol Investig. 2021;50:282&#x2013;294. doi: 10.1080/08820139.2020.1752712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08820139.2020.1752712</ArticleId><ArticleId IdType="pubmed">32429712</ArticleId></ArticleIdList></Reference><Reference><Citation>Tangtanatakul P, Thumarat C, Satproedprai N, Kunhapan P, Chaiyasung T, Klinchanhom S, et al. Meta-analysis of genome-wide association study identifies FBN2 as a novel locus associated with systemic lupus erythematosus in Thai population. Arthritis Res Ther. 2020;22:185. doi: 10.1186/s13075-020-02276-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-020-02276-y</ArticleId><ArticleId IdType="pmc">PMC7414652</ArticleId><ArticleId IdType="pubmed">32771030</ArticleId></ArticleIdList></Reference><Reference><Citation>Alarc&#xf3;n-Riquelme ME, Ziegler JT, Molineros J, Howard TD, Moreno-Estrada A, S&#xe1;nchez-Rodr&#xed;guez E, et al. Genome-wide association study in an Amerindian ancestry population reveals novel systemic lupus erythematosus risk loci and the role of European admixture. Arthritis Rheumatol. 2016;68:932&#x2013;943. doi: 10.1002/art.39504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39504</ArticleId><ArticleId IdType="pmc">PMC4829354</ArticleId><ArticleId IdType="pubmed">26606652</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng J, Yin J, Huang R, Petersen F, Yu X. Meta-analysis reveals an association of STAT4 polymorphisms with systemic autoimmune disorders and anti-dsDNA antibody. Hum Immunol. 2013;74:986&#x2013;992. doi: 10.1016/j.humimm.2013.04.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2013.04.034</ArticleId><ArticleId IdType="pubmed">23628400</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung SA, Taylor KE, Graham RR, Nititham J, Lee AT, Ortmann WA, et al. Differential genetic associations for systemic lupus erythematosus based on anti-dsDNA autoantibody production. PLoS Genet. 2011;7:e1001323. doi: 10.1371/journal.pgen.1001323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1001323</ArticleId><ArticleId IdType="pmc">PMC3048371</ArticleId><ArticleId IdType="pubmed">21408207</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolin K, Sandling JK, Zickert A, J&#xf6;nsen A, Sj&#xf6;wall C, Svenungsson E, et al. Association of STAT4 polymorphism with severe renal insufficiency in lupus nephritis. PLoS&#xa0;One. 2013;8:e84450. doi: 10.1371/journal.pone.0084450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0084450</ArticleId><ArticleId IdType="pmc">PMC3873995</ArticleId><ArticleId IdType="pubmed">24386384</ArticleId></ArticleIdList></Reference><Reference><Citation>Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L, Crow MK, Niewold TB. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol. 2009;182:34&#x2013;38. doi: 10.4049/jimmunol.182.1.34.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.182.1.34</ArticleId><ArticleId IdType="pmc">PMC2716754</ArticleId><ArticleId IdType="pubmed">19109131</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow MK, Ronnblom L. Type I interferons in host defence and inflammatory diseases. Lupus Sci Med. 2019;6:e000336. doi: 10.1136/lupus-2019-000336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2019-000336</ArticleId><ArticleId IdType="pmc">PMC6541752</ArticleId><ArticleId IdType="pubmed">31205729</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garc&#xed;a Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508&#x2013;519. doi: 10.1056/NEJMoa1112072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1112072</ArticleId><ArticleId IdType="pubmed">22873531</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandborn WJ, Su C, Sands BE, D&#x2019;Haens GR, Vermeire S, Schreiber S, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723&#x2013;1736. doi: 10.1056/NEJMoa1606910.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1606910</ArticleId><ArticleId IdType="pubmed">28467869</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasni SA, Gupta S, Davis M, Poncio E, Temesgen-Oyelakin Y, Carlucci PM, et al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun. 2021;12:3391. doi: 10.1038/s41467-021-23361-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23361-z</ArticleId><ArticleId IdType="pmc">PMC8185103</ArticleId><ArticleId IdType="pubmed">34099646</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahl L, Patel J, Layton M, Binks M, Hicks K, Leon G, et al. Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus. Lupus. 2016;25:1420&#x2013;1430. doi: 10.1177/0961203316640910.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203316640910</ArticleId><ArticleId IdType="pubmed">27055521</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven RF, Layton M, Kahl L, Schifano L, Hachulla E, Machado D, et al. DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184. Lupus. 2015;24:648&#x2013;649. doi: 10.1177/0961203315573347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203315573347</ArticleId><ArticleId IdType="pubmed">25724932</ArticleId></ArticleIdList></Reference><Reference><Citation>Feagan BG, Danese S, Loftus EV, Vermeire S, Schreiber S, Ritter T, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021;397:2372&#x2013;2384. doi: 10.1016/S0140-6736(21)00666-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00666-8</ArticleId><ArticleId IdType="pubmed">34090625</ArticleId></ArticleIdList></Reference><Reference><Citation>Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, Bartok B, Matzkies F, et al. Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 Randomized Clinical Trial. JAMA. 2019;322:315&#x2013;325. doi: 10.1001/jama.2019.9055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.9055</ArticleId><ArticleId IdType="pmc">PMC6652745</ArticleId><ArticleId IdType="pubmed">31334793</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen ML, Reyes Gonzaga J, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376:652&#x2013;662. doi: 10.1056/NEJMoa1608345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1608345</ArticleId><ArticleId IdType="pubmed">28199814</ArticleId></ArticleIdList></Reference><Reference><Citation>King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386:1687&#x2013;1699. doi: 10.1056/NEJMoa2110343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2110343</ArticleId><ArticleId IdType="pubmed">35334197</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156:1333&#x2013;1343. doi: 10.1001/jamadermatol.2020.3260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamadermatol.2020.3260</ArticleId><ArticleId IdType="pmc">PMC7527941</ArticleId><ArticleId IdType="pubmed">33001140</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384:795&#x2013;807. doi: 10.1056/NEJMoa2031994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2031994</ArticleId><ArticleId IdType="pmc">PMC7745180</ArticleId><ArticleId IdType="pubmed">33306283</ArticleId></ArticleIdList></Reference><Reference><Citation>Ely EW, Ramanan AV, Kartman CE, de Bono S, Liao R, Piruzeli MLB, et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respir Med. 2022;10:327&#x2013;336. doi: 10.1016/S2213-2600(22)00006-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00006-6</ArticleId><ArticleId IdType="pmc">PMC8813065</ArticleId><ArticleId IdType="pubmed">35123660</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392:222&#x2013;231. doi: 10.1016/S0140-6736(18)31363-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)31363-1</ArticleId><ArticleId IdType="pubmed">30043749</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xf6;rner T, van Vollenhoven RF, Doria A, Jia B, Ross Terres JA, Silk ME, et al. Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial. Arthritis Res Ther. 2022;24:112. doi: 10.1186/s13075-022-02794-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-022-02794-x</ArticleId><ArticleId IdType="pmc">PMC9109322</ArticleId><ArticleId IdType="pubmed">35578304</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xf6;rner T, Tanaka Y, Petri MA, Smolen JS, Wallace DJ, Dow ER, et al. Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. Lupus Sci Med. 2020;7:e000424. doi: 10.1136/lupus-2020-000424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2020-000424</ArticleId><ArticleId IdType="pmc">PMC7549481</ArticleId><ArticleId IdType="pubmed">33037080</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Vital EM, Petri M, van Vollenhoven R, Wallace DJ, Mosca M, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I) Lancet. 2023 doi: 10.1016/S0140-6736(22)02607-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)02607-1</ArticleId><ArticleId IdType="pubmed">36848918</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Bruce IN, D&#xf6;rner T, Tanaka Y, Morand EF, Kalunian KC, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II) Lancet. 2023 doi: 10.1016/S0140-6736(22)02546-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)02546-6</ArticleId><ArticleId IdType="pubmed">36848919</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand E, Pike M, Merrill JT, van Vollenhoven R, Werth VP, Hobar C, et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2023;75:242&#x2013;252. doi: 10.1002/art.42391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42391</ArticleId><ArticleId IdType="pmc">PMC10100399</ArticleId><ArticleId IdType="pubmed">36369798</ArticleId></ArticleIdList></Reference><Reference><Citation>CarneroContentti E, Correale J. Bruton&#x2019;s tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosis. Expert Opin Emerg Drugs. 2020;25:377&#x2013;381. doi: 10.1080/14728214.2020.1822817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728214.2020.1822817</ArticleId><ArticleId IdType="pubmed">32910702</ArticleId></ArticleIdList></Reference><Reference><Citation>Neys SFH, Hendriks RW, Corneth OBJ. Targeting Bruton&#x2019;s tyrosine kinase in inflammatory and autoimmune pathologies. Front Cell Dev Biol. 2021;9:668131. doi: 10.3389/fcell.2021.668131.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.668131</ArticleId><ArticleId IdType="pmc">PMC8213343</ArticleId><ArticleId IdType="pubmed">34150760</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang C, Tian D, Ren X, Ding S, Jia M, Xin M, et al. The development of Bruton&#x2019;s tyrosine kinase (BTK) inhibitors from 2012 to 2017: a mini-review. Eur J Med Chem. 2018;151:315&#x2013;326. doi: 10.1016/j.ejmech.2018.03.062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2018.03.062</ArticleId><ArticleId IdType="pubmed">29631132</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D, Gong H, Meng F. Recent advances in BTK inhibitors for the treatment of inflammatory and autoimmune diseases. Molecules. 2021;26:4907. doi: 10.3390/molecules26164907.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26164907</ArticleId><ArticleId IdType="pmc">PMC8399599</ArticleId><ArticleId IdType="pubmed">34443496</ArticleId></ArticleIdList></Reference><Reference><Citation>Rip J, de Bruijn MJW, Appelman MK, Pal Singh S, Hendriks RW, Corneth OBJ. Toll-like receptor signaling drives Btk-mediated autoimmune disease. Front Immunol. 2019;10:95. doi: 10.3389/fimmu.2019.00095.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00095</ArticleId><ArticleId IdType="pmc">PMC6363707</ArticleId><ArticleId IdType="pubmed">30761150</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-Herrera G, Vargas-Hern&#xe1;ndez A, Gonz&#xe1;lez-Serrano ME, Berr&#xf3;n-Ruiz L, Rodr&#xed;guez-Alba JC, Espinosa-Rosales F, et al. Bruton&#x2019;s tyrosine kinase: an integral protein of B cell development that also has an essential role in the innate immune system. J Leukoc Biol. 2014;95:243&#x2013;250. doi: 10.1189/jlb.0513307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.0513307</ArticleId><ArticleId IdType="pubmed">24249742</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuehn HS, R&#xe5;dinger M, Brown JM, Ali K, Vanhaesebroeck B, Beaven MA, et al. Btk-dependent Rac activation and actin rearrangement following FcepsilonRI aggregation promotes enhanced chemotactic responses of mast cells. J Cell Sci. 2010;123:2576&#x2013;2585. doi: 10.1242/jcs.071043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.071043</ArticleId><ArticleId IdType="pmc">PMC2908047</ArticleId><ArticleId IdType="pubmed">20587594</ArticleId></ArticleIdList></Reference><Reference><Citation>Quek LS, Bolen J, Watson SP. A role for Bruton&#x2019;s tyrosine kinase (Btk) in platelet activation by collagen. Curr Biol. 1998;8:1137&#x2013;1140. doi: 10.1016/S0960-9822(98)70471-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0960-9822(98)70471-3</ArticleId><ArticleId IdType="pubmed">9778529</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinohara M, Koga T, Okamoto K, Sakaguchi S, Arai K, Yasuda H, et al. Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell. 2008;132:794&#x2013;806. doi: 10.1016/j.cell.2007.12.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.12.037</ArticleId><ArticleId IdType="pubmed">18329366</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Chen C, Wang D, Zhang J, Zhang T. Emerging small-molecule inhibitors of the Bruton&#x2019;s tyrosine kinase (BTK): current development. Eur J Med Chem. 2021;217:113329. doi: 10.1016/j.ejmech.2021.113329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2021.113329</ArticleId><ArticleId IdType="pubmed">33740548</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen BW, Zaha VG, Awan FT. Cardiotoxicity of BTK inhibitors: ibrutinib and beyond. Expert Rev Hematol. 2022;15:321&#x2013;331. doi: 10.1080/17474086.2022.2067526.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17474086.2022.2067526</ArticleId><ArticleId IdType="pubmed">35437106</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson PA, Burger JA. Bruton&#x2019;s tyrosine kinase inhibitors: first and second generation agents for patients with chronic lymphocytic leukemia (CLL) Expert Opin Investig Drugs. 2018;27:31&#x2013;42. doi: 10.1080/13543784.2018.1404027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543784.2018.1404027</ArticleId><ArticleId IdType="pubmed">29125406</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalmers SA, Glynn E, Garcia SJ, Panzenbeck M, Pelletier J, Dimock J, et al. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis. Clin Immunol. 2018;197:205&#x2013;218. doi: 10.1016/j.clim.2018.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2018.10.008</ArticleId><ArticleId IdType="pmc">PMC6384222</ArticleId><ArticleId IdType="pubmed">30339790</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YY, Park KT, Jang SY, Lee KH, Byun JY, Suh KH, et al. HM71224, a selective Bruton&#x2019;s tyrosine kinase inhibitor, attenuates the development of murine lupus. Arthritis Res Ther. 2017;19:211. doi: 10.1186/s13075-017-1402-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-017-1402-1</ArticleId><ArticleId IdType="pmc">PMC5615432</ArticleId><ArticleId IdType="pubmed">28950886</ArticleId></ArticleIdList></Reference><Reference><Citation>Rankin AL, Seth N, Keegan S, Andreyeva T, Cook TA, Edmonds J, et al. Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis. J Immunol. 2013;191:4540&#x2013;4550. doi: 10.4049/jimmunol.1301553.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1301553</ArticleId><ArticleId IdType="pubmed">24068666</ArticleId></ArticleIdList></Reference><Reference><Citation>Mina-Osorio P, LaStant J, Keirstead N, Whittard T, Ayala J, Stefanova S, et al. Suppression of glomerulonephritis in lupus-prone NZB &#xd7; NZW mice by RN486, a selective inhibitor of Bruton&#x2019;s tyrosine kinase. Arthritis Rheumatol. 2013;65:2380&#x2013;2391. doi: 10.1002/art.38047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38047</ArticleId><ArticleId IdType="pubmed">23754328</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalmers SA, Wen J, Doerner J, Stock A, Cuda CM, Makinde HM, et al. Highly selective inhibition of Bruton&#x2019;s tyrosine kinase attenuates skin and brain disease in murine lupus. Arthritis Res Ther. 2018;20:10. doi: 10.1186/s13075-017-1500-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-017-1500-0</ArticleId><ArticleId IdType="pmc">PMC5785891</ArticleId><ArticleId IdType="pubmed">29370834</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutcheson J, Vanarsa K, Bashmakov A, Grewal S, Sajitharan D, Chang BY, et al. Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus. Arthritis Res Ther. 2012;14:R243. doi: 10.1186/ar4086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar4086</ArticleId><ArticleId IdType="pmc">PMC3674619</ArticleId><ArticleId IdType="pubmed">23136880</ArticleId></ArticleIdList></Reference><Reference><Citation>Bender AT, Pereira A, Fu K, Samy E, Wu Y, Liu-Bujalski L, et al. Btk inhibition treats TLR7/IFN driven murine lupus. Clin Immunol. 2016;164:65&#x2013;77. doi: 10.1016/j.clim.2016.01.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2016.01.012</ArticleId><ArticleId IdType="pubmed">26821304</ArticleId></ArticleIdList></Reference><Reference><Citation>Haselmayer P, Camps M, Liu-Bujalski L, Nguyen N, Morandi F, Head J, et al. Efficacy and pharmacodynamic modeling of the BTK inhibitor evobrutinib in autoimmune disease models. J Immunol. 2019;202:2888&#x2013;2906. doi: 10.4049/jimmunol.1800583.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1800583</ArticleId><ArticleId IdType="pmc">PMC6500888</ArticleId><ArticleId IdType="pubmed">30988116</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong W, Deng W, Sun Y, Huang S, Zhang Z, Shi B, et al. Increased expression of Bruton&#x2019;s tyrosine kinase in peripheral blood is associated with lupus nephritis. Clin Rheumatol. 2018;37:43&#x2013;49. doi: 10.1007/s10067-017-3717-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-017-3717-3</ArticleId><ArticleId IdType="pubmed">28612243</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace DJ, D&#xf6;rner T, Pisetsky DS, Sanchez-Guerrero J, Patel AC, Parsons-Rich D, et al. Efficacy and safety of the Bruton&#x2019;s tyrosine kinase inhibitor evobrutinib in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled dose-ranging trial. ACR Open Rheumatol. 2023;5:38&#x2013;48. doi: 10.1002/acr2.11511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr2.11511</ArticleId><ArticleId IdType="pmc">PMC9837396</ArticleId><ArticleId IdType="pubmed">36530019</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen S, Tuckwell K, Katsumoto TR, Zhao R, Galanter J, Lee C, et al. Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: a randomized, double-blind, phase II trial (ANDES Study) Arthritis Rheumatol. 2020;72:1435&#x2013;1446. doi: 10.1002/art.41275.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41275</ArticleId><ArticleId IdType="pmc">PMC7496340</ArticleId><ArticleId IdType="pubmed">32270926</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrd JC, Smith S, Wagner-Johnston N, Sharman J, Chen AI, Advani R, et al. First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget. 2018;9:13023&#x2013;13035. doi: 10.18632/oncotarget.24310.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.24310</ArticleId><ArticleId IdType="pmc">PMC5849192</ArticleId><ArticleId IdType="pubmed">29560128</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenberg D, Furie R, Jones NS, Guibord P, Galanter J, Lee C, et al. Efficacy, safety, and pharmacodynamic effects of the Bruton&#x2019;s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2021;73:1835&#x2013;1846. doi: 10.1002/art.41811.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41811</ArticleId><ArticleId IdType="pubmed">34042314</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Zhu X, Liu S, Zhang X, Xie C, Fu Z, et al. Orelabrutinib, an irreversible inhibitor of Bruton&#x2019;s tyrosine kinase (btk), for the treatment of systemic lupus erythematosus (SLE): results of a randomized, double-blind, placebo-controlled, phase Ib/IIa dose-finding study. Ann Rheum Dis. 2022;81(Suppl. 1):210.</Citation></Reference><Reference><Citation>Deng GM, Kyttaris VC, Tsokos GC. Targeting Syk in autoimmune rheumatic diseases. Front Immunol. 2016;7:78. doi: 10.3389/fimmu.2016.00078.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2016.00078</ArticleId><ArticleId IdType="pmc">PMC4779881</ArticleId><ArticleId IdType="pubmed">27014261</ArticleId></ArticleIdList></Reference><Reference><Citation>Aouar B, Kovarova D, Letard S, Font-Haro A, Florentin J, Weber J, et al. Dual role of the tyrosine kinase Syk in regulation of Toll-like receptor signaling in plasmacytoid dendritic cells. PLoS&#xa0;One. 2016;11:e0156063. doi: 10.1371/journal.pone.0156063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0156063</ArticleId><ArticleId IdType="pmc">PMC4892542</ArticleId><ArticleId IdType="pubmed">27258042</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly V, Genovese M. Novel small molecule therapeutics in rheumatoid arthritis. Rheumatology (Oxford) 2013;52:1155&#x2013;1162. doi: 10.1093/rheumatology/kes367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kes367</ArticleId><ArticleId IdType="pubmed">23297340</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng GM, Liu L, Bahjat FR, Pine PR, Tsokos GC. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheumatol. 2010;62:2086&#x2013;2092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902591</ArticleId><ArticleId IdType="pubmed">20222110</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahjat FR, Pine PR, Reitsma A, Cassafer G, Baluom M, Grillo S, et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheumatol. 2008;58:1433&#x2013;1444. doi: 10.1002/art.23428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23428</ArticleId><ArticleId IdType="pubmed">18438845</ArticleId></ArticleIdList></Reference><Reference><Citation>Pohlmeyer CW, Shang C, Han P, Cui ZH, Jones RM, Clarke AS, et al. Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis. BMC Rheumatol. 2021;5:15. doi: 10.1186/s41927-021-00178-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41927-021-00178-3</ArticleId><ArticleId IdType="pmc">PMC8008554</ArticleId><ArticleId IdType="pubmed">33781343</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitai M, Fukuda N, Ueno T, Endo M, Maruyama T, Abe M, et al. Effects of a spleen tyrosine kinase inhibitor on progression of the lupus nephritis in mice. J Pharmacol Sci. 2017;134:29&#x2013;36. doi: 10.1016/j.jphs.2017.02.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jphs.2017.02.015</ArticleId><ArticleId IdType="pubmed">28479222</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho S, Jang E, Yoon T, Hwang H, Youn J. A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models. Clin Exp Immunol. 2022;211:31&#x2013;45. doi: 10.1093/cei/uxac096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cei/uxac096</ArticleId><ArticleId IdType="pmc">PMC9993459</ArticleId><ArticleId IdType="pubmed">36346114</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsukane R, Suetsugu K, Hirota T, Ieiri I. Clinical pharmacokinetics and pharmacodynamics of fostamatinib and its active moiety R406. Clin Pharmacokinet. 2022;61:955&#x2013;972. doi: 10.1007/s40262-022-01135-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-022-01135-0</ArticleId><ArticleId IdType="pmc">PMC9250994</ArticleId><ArticleId IdType="pubmed">35781630</ArticleId></ArticleIdList></Reference><Reference><Citation>Paik J. Fostamatinib: a review in chronic immune thrombocytopenia. Drugs. 2021;81:935&#x2013;943. doi: 10.1007/s40265-021-01524-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-021-01524-y</ArticleId><ArticleId IdType="pubmed">33970459</ArticleId></ArticleIdList></Reference><Reference><Citation>Genovese MC, van der Heijde DM, Keystone EC, Spindler AJ, Benhamou C, Kavanaugh A, et al. A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-&#x3b1; antagonist. J Rheumatol. 2014;41:2120&#x2013;2128. doi: 10.3899/jrheum.140238.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.140238</ArticleId><ArticleId IdType="pubmed">25225285</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinblatt ME, Genovese MC, Ho M, Hollis S, Rosiak-Jedrychowicz K, Kavanaugh A, et al. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheumatol. 2014;66:3255&#x2013;3264. doi: 10.1002/art.38851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38851</ArticleId><ArticleId IdType="pubmed">25223724</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivitz AJ, Mehta DP, Matzkies F, Mozaffarian A, Kunder R, Di Paolo J, et al. GS-9876, a novel, highly selective, SYK inhibitor in patients with active rheumatoid arthritis: safety, tolerability and efficacy results of a phase 2 study [abstract 2518]. Arthritis Rheumatol. 2018;70(Suppl. 9).</Citation></Reference><Reference><Citation>Grammatikos AP, Ghosh D, Devlin A, Kyttaris VC, Tsokos GC. Spleen tyrosine kinase (Syk) regulates systemic lupus erythematosus (SLE) T cell signaling. PLoS&#xa0;One. 2013;8:e74550. doi: 10.1371/journal.pone.0074550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0074550</ArticleId><ArticleId IdType="pmc">PMC3754955</ArticleId><ArticleId IdType="pubmed">24013589</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnan S, Juang YT, Chowdhury B, Magilavy A, Fisher CU, Nguyen H, et al. Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells. J Immunol. 2008;181:8145&#x2013;8152. doi: 10.4049/jimmunol.181.11.8145.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.181.11.8145</ArticleId><ArticleId IdType="pmc">PMC2586973</ArticleId><ArticleId IdType="pubmed">19018007</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleischer SJ, Giesecke C, Mei HE, Lipsky PE, Daridon C, D&#xf6;rner T. Increased frequency of a unique spleen tyrosine kinase bright memory B cell population in systemic lupus erythematosus. Arthritis Rheumatol. 2014;66:3424&#x2013;3435. doi: 10.1002/art.38854.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38854</ArticleId><ArticleId IdType="pubmed">25156507</ArticleId></ArticleIdList></Reference><Reference><Citation>Werth VP, Fleischmann R, Robern M, Touma Z, Tiamiyu I, Gurtovaya O, et al. Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study. Rheumatology (Oxford) 2022;61:2413&#x2013;2423. doi: 10.1093/rheumatology/keab685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab685</ArticleId><ArticleId IdType="pmc">PMC9157055</ArticleId><ArticleId IdType="pubmed">34498056</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker M, Chaichian Y, Genovese M, Derebail V, Rao P, Chatham W, et al. Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy. RMD Open. 2020;6:e001490. doi: 10.1136/rmdopen-2020-001490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2020-001490</ArticleId><ArticleId IdType="pmc">PMC7780527</ArticleId><ArticleId IdType="pubmed">33380521</ArticleId></ArticleIdList></Reference><Reference><Citation>Manasanch EE, Orlowski RZ. Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol. 2017;14:417&#x2013;433. doi: 10.1038/nrclinonc.2016.206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrclinonc.2016.206</ArticleId><ArticleId IdType="pmc">PMC5828026</ArticleId><ArticleId IdType="pubmed">28117417</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Fang Y, Fan RA, Kirk CJ. Proteasome inhibitors and their pharmacokinetics, pharmacodynamics, and metabolism. Int J Mol Sci. 2021;22:11595. doi: 10.3390/ijms222111595.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222111595</ArticleId><ArticleId IdType="pmc">PMC8583966</ArticleId><ArticleId IdType="pubmed">34769030</ArticleId></ArticleIdList></Reference><Reference><Citation>Eskandari SK, Seelen MAJ, Lin G, Azzi JR. The immunoproteasome: an old player with a novel and emerging role in alloimmunity. Am J Transplant. 2017;17:3033&#x2013;3039. doi: 10.1111/ajt.14435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.14435</ArticleId><ArticleId IdType="pubmed">28719024</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiepe F, Radbruch A. Plasma cells as an innovative target in autoimmune disease with renal manifestations. Nat Rev Nephrol. 2016;12:232&#x2013;240. doi: 10.1038/nrneph.2016.20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneph.2016.20</ArticleId><ArticleId IdType="pubmed">26923204</ArticleId></ArticleIdList></Reference><Reference><Citation>Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med. 2008;14:748&#x2013;755. doi: 10.1038/nm1763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1763</ArticleId><ArticleId IdType="pubmed">18542049</ArticleId></ArticleIdList></Reference><Reference><Citation>Seavey MM, Lu LD, Stump KL, Wallace NH, Ruggeri BA. Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE. Int Immunopharmacol. 2012;12:257&#x2013;270. doi: 10.1016/j.intimp.2011.11.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2011.11.019</ArticleId><ArticleId IdType="pubmed">22178195</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SW, Kim BS. Comparison of therapeutic efficacy between bortezomib and combination treatment of prednisolone and mycophenolate mofetil on nephritis in NZB/WF1 mice. Clin Exp Rheumatol. 2010;28:393&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">20497633</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, Owen T, et al. Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheumatol. 2012;64:493&#x2013;503. doi: 10.1002/art.33333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.33333</ArticleId><ArticleId IdType="pmc">PMC4584406</ArticleId><ArticleId IdType="pubmed">21905015</ArticleId></ArticleIdList></Reference><Reference><Citation>Muchamuel T, Anderl JL, Fan RA, Johnson HWB, Kirk CJ, Lowe ET. KZR-616, a selective inhibitor of the immunoproteasome, blocks the disease progression in multiple models of systemic lupus erythematosus (SLE) Ann Rheum Dis. 2018;77(Suppl):A685.</Citation></Reference><Reference><Citation>Walhelm T, Gunnarsson I, Heijke R, Leonard D, Trysberg E, Eriksson P, et al. Clinical experience of proteasome inhibitor bortezomib regarding efficacy and safety in severe systemic lupus erythematosus: a nationwide study. Front Immunol. 2021;12:756941. doi: 10.3389/fimmu.2021.756941.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.756941</ArticleId><ArticleId IdType="pmc">PMC8517506</ArticleId><ArticleId IdType="pubmed">34659263</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander T, Sarfert R, Klotsche J, K&#xfc;hl AA, Rubbert-Roth A, Lorenz HM, et al. The proteasome inhibitor bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis. 2015;74:1474&#x2013;1478. doi: 10.1136/annrheumdis-2014-206016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-206016</ArticleId><ArticleId IdType="pmc">PMC4484251</ArticleId><ArticleId IdType="pubmed">25710470</ArticleId></ArticleIdList></Reference><Reference><Citation>Quartuccio L, Rupolo M, Michieli M, De Vita S. Efficacy and tolerability of repeated cycles of a once-weekly regimen of bortezomib in lupus. Rheumatology (Oxford) 2014;53:381&#x2013;382. doi: 10.1093/rheumatology/ket284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ket284</ArticleId><ArticleId IdType="pubmed">23962626</ArticleId></ArticleIdList></Reference><Reference><Citation>Segarra A, Arredondo KV, Jaramillo J, Jatem E, Salcedo MT, Agraz I, et al. Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience. Lupus. 2020;29:118&#x2013;125. doi: 10.1177/0961203319896018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319896018</ArticleId><ArticleId IdType="pubmed">31865857</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Liu Z, Huang L, Hou J, Zhou M, Huang X, et al. The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis. Lupus. 2017;26:952&#x2013;958. doi: 10.1177/0961203316686703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203316686703</ArticleId><ArticleId IdType="pubmed">28059023</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander T, Cheng Q, Klotsche J, Khodadadi L, Waka A, Biesen R, et al. Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors. Eur J Immunol. 2018;48:1573&#x2013;1579. doi: 10.1002/eji.201847492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201847492</ArticleId><ArticleId IdType="pubmed">29979809</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii T, Tanaka Y, Kawakami A, Saito K, Ichinose K, Fujii H, et al. Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus. Mod Rheumatol. 2018;28:986&#x2013;992. doi: 10.1080/14397595.2018.1432331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14397595.2018.1432331</ArticleId><ArticleId IdType="pubmed">29363990</ArticleId></ArticleIdList></Reference><Reference><Citation>Khodadadi L, Cheng Q, Alexander T, Sercan-Alp &#xd6;, Klotsche J, Radbruch A, et al. Bortezomib plus continuous B cell depletion results in sustained plasma cell depletion and amelioration of lupus nephritis in NZB/W F1 mice. PLoS&#xa0;One. 2015;10:e0135081. doi: 10.1371/journal.pone.0135081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0135081</ArticleId><ArticleId IdType="pmc">PMC4529137</ArticleId><ArticleId IdType="pubmed">26252021</ArticleId></ArticleIdList></Reference><Reference><Citation>Sj&#xf6;wall C, Hjorth M, Eriksson P. Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases. Lupus. 2017;26:1333&#x2013;1338. doi: 10.1177/0961203317691371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317691371</ArticleId><ArticleId IdType="pubmed">28162031</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Y, Johnson H, Anderl JL, Muchamuel T, McMinn D, Morisseau C, et al. Role of epoxide hydrolases and cytochrome P450s on metabolism of KZR-616, a first-in-class selective inhibitor of the immunoproteasome. Drug Metab Dispos. 2021;49:810&#x2013;821. doi: 10.1124/dmd.120.000307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/dmd.120.000307</ArticleId><ArticleId IdType="pubmed">34234005</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Parikh S, Maiquez A, Khan A, Moreno O, Soneira M, et al. Treatment of SLE with the immunoproteasome inhibitor KZR-616: results from the first four cohorts of the MISSION study, an open-label phase 1b dose escalation trial. Ann Rheum Dis. 2020;79(Suppl. 1):1482.</Citation></Reference><Reference><Citation>Richardson PG, Mateos MV, Vangsted AJ, Ramasamy K, Abildgaard N, Ho PJ, et al. The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory disease. Expert Rev Proteomics. 2022;19:235&#x2013;246. doi: 10.1080/14789450.2022.2142564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14789450.2022.2142564</ArticleId><ArticleId IdType="pubmed">36342226</ArticleId></ArticleIdList></Reference><Reference><Citation>Matyskiela ME, Zhang W, Man HW, Muller G, Khambatta G, Baculi F, et al. A cereblon modulator (CC-220) with improved degradation of Ikaros and Aiolos. J Med Chem. 2018;61:535&#x2013;542. doi: 10.1021/acs.jmedchem.6b01921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.6b01921</ArticleId><ArticleId IdType="pubmed">28425720</ArticleId></ArticleIdList></Reference><Reference><Citation>John LB, Ward AC. The Ikaros gene family: transcriptional regulators of hematopoiesis and immunity. Mol Immunol. 2011;48:1272&#x2013;1278. doi: 10.1016/j.molimm.2011.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2011.03.006</ArticleId><ArticleId IdType="pubmed">21477865</ArticleId></ArticleIdList></Reference><Reference><Citation>Lessard CJ, Adrianto I, Ice JA, Wiley GB, Kelly JA, Glenn SB, et al. Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study. Am J Hum Genet. 2012;90:648&#x2013;660. doi: 10.1016/j.ajhg.2012.02.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2012.02.023</ArticleId><ArticleId IdType="pmc">PMC3322228</ArticleId><ArticleId IdType="pubmed">22464253</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Ahlford A, J&#xe4;rvinen TM, Nordmark G, Eloranta ML, Gunnarsson I, et al. Genes identified in Asian SLE GWASs are also associated with SLE in Caucasian populations. Eur J Hum Genet. 2013;21:994&#x2013;999. doi: 10.1038/ejhg.2012.277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejhg.2012.277</ArticleId><ArticleId IdType="pmc">PMC3746253</ArticleId><ArticleId IdType="pubmed">23249952</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer PH, Ye Y, Wu L, Kosek J, Ringheim G, Yang Z, et al. Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus. Ann Rheum Dis. 2018;77:1516&#x2013;1523. doi: 10.1136/annrheumdis-2017-212916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-212916</ArticleId><ArticleId IdType="pmc">PMC6161670</ArticleId><ArticleId IdType="pubmed">29945920</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivellese F, Manou-Stathopoulou S, Mauro D, Goldmann K, Pyne D, Rajakariar R, et al. Effects of targeting the transcription factors Ikaros and Aiolos on B cell activation and differentiation in systemic lupus erythematosus. Lupus Sci Med. 2021;8:e000445. doi: 10.1136/lupus-2020-000445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2020-000445</ArticleId><ArticleId IdType="pmc">PMC7970264</ArticleId><ArticleId IdType="pubmed">33727237</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SW, Park YB, Yang J, Park KH, Lee SK, Choi KH, et al. Attenuation of nephritis in lupus-prone mice by thalidomide. Rheumatology (Oxford) 2012;51:2131&#x2013;2140. doi: 10.1093/rheumatology/kes227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kes227</ArticleId><ArticleId IdType="pubmed">22923758</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim EJ, Lee JG, Kim JY, Song SH, Joo DJ, Huh KH, et al. Enhanced immune-modulatory effects of thalidomide and dexamethasone co-treatment on T cell subsets. Immunology. 2017;152:628&#x2013;637. doi: 10.1111/imm.12804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.12804</ArticleId><ArticleId IdType="pmc">PMC5680070</ArticleId><ArticleId IdType="pubmed">28758197</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuki EFN, Silva CA, Aikawa NE, Romiti R, Heise CO, Bonfa E, et al. Thalidomide and lenalidomide for refractory systemic/cutaneous lupus erythematosus treatment: a narrative review of literature for clinical practice. J Clin Rheumatol. 2021;27:248&#x2013;259. doi: 10.1097/RHU.0000000000001160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RHU.0000000000001160</ArticleId><ArticleId IdType="pubmed">31693649</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Garcia D, Cornell RF, Gailani D, Laubach J, Maglio ME, et al. Cardiovascular and thrombotic complications of novel multiple myeloma therapies: a review. JAMA Oncol. 2017;3:980&#x2013;988. doi: 10.1001/jamaoncol.2016.3350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2016.3350</ArticleId><ArticleId IdType="pubmed">27632640</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie RA, Hough DR, Gaudy A, Ye Y, Korish S, Delev N, et al. Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study. Lupus Sci Med. 2022;9:e000581. doi: 10.1136/lupus-2021-000581.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000581</ArticleId><ArticleId IdType="pmc">PMC8852715</ArticleId><ArticleId IdType="pubmed">35169036</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT, Werth VP, Furie R, van Vollenhoven R, D&#xf6;rner T, Petronijevic M, et al. Phase 2 trial of iberdomide in systemic lupus erythematosus. N Engl J Med. 2022;386:1034&#x2013;1045. doi: 10.1056/NEJMoa2106535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2106535</ArticleId><ArticleId IdType="pubmed">35294813</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsky PE, van Vollenhoven R, D&#xf6;rner T, Werth VP, Merrill JT, Furie R, et al. Biological impact of iberdomide in patients with active systemic lupus erythematosus. Ann Rheum Dis. 2022;81:1136&#x2013;1142. doi: 10.1136/annrheumdis-2022-222212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2022-222212</ArticleId><ArticleId IdType="pmc">PMC9279852</ArticleId><ArticleId IdType="pubmed">35477518</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez-Jeldres T, Alvarez-Lobos M, Rivera-Nieves J. Targeting sphingosine-1-phosphate signaling in immune-mediated diseases: beyond multiple sclerosis. Drugs. 2021;81:985&#x2013;1002. doi: 10.1007/s40265-021-01528-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-021-01528-8</ArticleId><ArticleId IdType="pmc">PMC8116828</ArticleId><ArticleId IdType="pubmed">33983615</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Wang J, Zhang C, Ding P, Tian S, Chen J, et al. Sphingosine 1-phosphate receptor, a new therapeutic direction in different diseases. Biomed Pharmacother. 2022;153:113341. doi: 10.1016/j.biopha.2022.113341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2022.113341</ArticleId><ArticleId IdType="pubmed">35785704</ArticleId></ArticleIdList></Reference><Reference><Citation>Strasser DS, Froidevaux S, Sippel V, Gerossier E, Grieder U, Pierlot GM, et al. Preclinical to clinical translation of cenerimod, a novel S1P1 receptor modulator, in systemic lupus erythematosus. RMD Open. 2020;6:e001261. doi: 10.1136/rmdopen-2020-001261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2020-001261</ArticleId><ArticleId IdType="pmc">PMC7722385</ArticleId><ArticleId IdType="pubmed">32917831</ArticleId></ArticleIdList></Reference><Reference><Citation>Ando S, Amano H, Amano E, Minowa K, Watanabe T, Nakano S, et al. FTY720 exerts a survival advantage through the prevention of end-stage glomerular inflammation in lupus-prone BXSB mice. Biochem Biophys Res Commun. 2010;394:804&#x2013;810. doi: 10.1016/j.bbrc.2010.03.078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2010.03.078</ArticleId><ArticleId IdType="pubmed">20233577</ArticleId></ArticleIdList></Reference><Reference><Citation>Okazaki H, Hirata D, Kamimura T, Sato H, Iwamoto M, Yoshio T, et al. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. J Rheumatol. 2002;29:707&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pubmed">11950011</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenderfer SE, Stepkowski SM, Braun MC. Increased survival and reduced renal injury in MRL/lpr mice treated with a novel sphingosine-1-phosphate receptor agonist. Kidney Int. 2008;74:1319&#x2013;1326. doi: 10.1038/ki.2008.396.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2008.396</ArticleId><ArticleId IdType="pmc">PMC3520442</ArticleId><ArticleId IdType="pubmed">18769369</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugahara K, Maeda Y, Shimano K, Murase M, Mochiduki S, Takemoto K, et al. Amiselimod (MT-1303), a novel sphingosine 1-phosphate receptor-1 modulator, potently inhibits the progression of lupus nephritis in two murine SLE models. J Immunol Res. 2019;2019:5821589. doi: 10.1155/2019/5821589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/5821589</ArticleId><ArticleId IdType="pmc">PMC6942851</ArticleId><ArticleId IdType="pubmed">31930150</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor Meadows KR, Steinberg MW, Clemons B, Stokes ME, Opiteck GJ, Peach R, et al. Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus. PLoS&#xa0;One. 2018;13:e0193236. doi: 10.1371/journal.pone.0193236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0193236</ArticleId><ArticleId IdType="pmc">PMC5880347</ArticleId><ArticleId IdType="pubmed">29608575</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki S, Li XK, Shinomiya T, Enosawa S, Amemiya H, Amari M, et al. The in vivo induction of lymphocyte apoptosis in MRL-lpr/lpr mice treated with FTY720. Clin Exp Immunol. 1997;107:103&#x2013;111. doi: 10.1046/j.1365-2249.1997.d01-885.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2249.1997.d01-885.x</ArticleId><ArticleId IdType="pmc">PMC1904563</ArticleId><ArticleId IdType="pubmed">9010264</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi D, Tian T, Yao S, Cao K, Zhu X, Zhang M, et al. FTY720 attenuates behavioral deficits in a murine model of systemic lupus erythematosus. Brain Behav Immun. 2018;70:293&#x2013;304. doi: 10.1016/j.bbi.2018.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2018.03.009</ArticleId><ArticleId IdType="pubmed">29548997</ArticleId></ArticleIdList></Reference><Reference><Citation>Mike EV, Makinde HM, Der E, Stock A, Gulinello M, Gadhvi GT, et al. Neuropsychiatric systemic lupus erythematosus is dependent on sphingosine-1-phosphate signaling. Front Immunol. 2018;9:2189. doi: 10.3389/fimmu.2018.02189.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02189</ArticleId><ArticleId IdType="pmc">PMC6168636</ArticleId><ArticleId IdType="pubmed">30319641</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y, Kondo K, Ichibori A, Yanai Y, Susuta Y, Inoue S, et al. Amiselimod, a sphingosine 1-phosphate receptor-1 modulator, for systemic lupus erythematosus: a multicenter, open-label exploratory study. Lupus. 2020;29:1902&#x2013;1913. doi: 10.1177/0961203320966385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320966385</ArticleId><ArticleId IdType="pubmed">33115374</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermann V, Batalov A, Smakotina S, Juif PE, Cornelisse P. First use of cenerimod, a selective S1P1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study. Lupus Sci Med. 2019;6:e000354. doi: 10.1136/lupus-2019-000354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2019-000354</ArticleId><ArticleId IdType="pmc">PMC6861098</ArticleId><ArticleId IdType="pubmed">31798918</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103&#x2013;1112. doi: 10.1681/ASN.2008101028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2008101028</ArticleId><ArticleId IdType="pmc">PMC2678035</ArticleId><ArticleId IdType="pubmed">19369404</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353:2219&#x2013;2228. doi: 10.1056/NEJMoa043731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa043731</ArticleId><ArticleId IdType="pubmed">16306519</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginzler E, Guedes Barbosa LS, D&#x2019;Cruz D, Furie R, Maksimowicz-McKinnon K, Oates J, et al. Phase III/IV, randomized, fifty-two-week study of the efficacy and safety of belimumab in patients of black African ancestry with systemic lupus erythematosus. Arthritis Rheumatol. 2022;74:112&#x2013;123. doi: 10.1002/art.41900.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41900</ArticleId><ArticleId IdType="pmc">PMC9300099</ArticleId><ArticleId IdType="pubmed">34164944</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382:211&#x2013;221. doi: 10.1056/NEJMoa1912196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1912196</ArticleId><ArticleId IdType="pubmed">31851795</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie RA, Morand EF, Bruce IN, Manzi S, Kalunian KC, Vital EM, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1:e208&#x2013;e219. doi: 10.1016/S2665-9913(19)30076-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(19)30076-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Vital EM, Merrill JT, Morand EF, Furie RA, Bruce IN, Tanaka Y, et al. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann Rheum Dis. 2022;81:951&#x2013;961. doi: 10.1136/annrheumdis-2021-221425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221425</ArticleId><ArticleId IdType="pmc">PMC9213795</ArticleId><ArticleId IdType="pubmed">35338035</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh SV, Malvar A, Song H, Shapiro J, Mejia-Vilet JM, Ayoub I, et al. Molecular profiling of kidney compartments from serial biopsies differentiate treatment responders from non-responders in lupus nephritis. Kidney Int. 2022;102(4):845&#x2013;865. doi: 10.1016/j.kint.2022.05.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2022.05.033</ArticleId><ArticleId IdType="pmc">PMC9613357</ArticleId><ArticleId IdType="pubmed">35788359</ArticleId></ArticleIdList></Reference><Reference><Citation>Der E, Suryawanshi H, Morozov P, Kustagi M, Goilav B, Ranabothu S, et al. Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nat Immunol. 2019;20:915&#x2013;927. doi: 10.1038/s41590-019-0386-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-019-0386-1</ArticleId><ArticleId IdType="pmc">PMC6584054</ArticleId><ArticleId IdType="pubmed">31110316</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok CC, Mohan C. Urinary biomarkers in lupus nephritis: are we there yet? Arthritis Rheumatol. 2021;73:194&#x2013;196. doi: 10.1002/art.41508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41508</ArticleId><ArticleId IdType="pubmed">32892509</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok CC. The dawn of a new era of therapies in systemic lupus erythematosus. Rheumatol Immunol Res. 2020;1:31&#x2013;37. doi: 10.2478/rir-2020-0005.</Citation><ArticleIdList><ArticleId IdType="doi">10.2478/rir-2020-0005</ArticleId><ArticleId IdType="pmc">PMC9524766</ArticleId><ArticleId IdType="pubmed">36465076</ArticleId></ArticleIdList></Reference><Reference><Citation>Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316&#x2013;326. doi: 10.1056/NEJMoa2109927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2109927</ArticleId><ArticleId IdType="pubmed">35081280</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>